Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
This study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these comorbidities. Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.PMID:37576545 | PMC:PMC10415861 | DOI:10.4330/wjc.v15.i7.328
Source: World Journal of Cardiology - Category: Cardiology Authors: Jose Arriola-Montenegro Renato Beas Renato Cerna-Viacava Andres Chaponan-Lavalle Karla Hernandez Randich Diego Chambergo-Michilot Herson Flores Sanga Pornthira Mutirangura Source Type: research
More News: Alcoholism | Beta-Blockers | Cardiology | Diovan | Fatty Liver Disease (FLD) | Heart | Heart Failure | Hydralazine | Liver | Liver Disease | Montenegro Health | Non-alcoholic Fatty Liver Diseases (NAFLD) | Sodium | Study | Urology & Nephrology